#United States #New York #Class Action #Pomerantz Law #Rocket Pharmaceuticals

Investor Alert: Class Action Filed Against Rocket Pharmaceuticals

On August 6, 2025, the renowned Pomerantz Law Firm announced a significant class action lawsuit concerning Rocket Pharmaceuticals, Inc., a company listed on NASDAQ as RCKT. This legal action has emerged following alarming developments related to the company's investigational gene therapy program, which have raised serious questions about potential securities fraud and other unlawful practices by the company and its executives.

Background of the Case

Investors who faced losses due to Rocket's stock performance are encouraged to connect with Danielle Peyton from Pomerantz at email or call 646-581-9980. The firm stresses the urgency of contacting them by August 11, 2025, should you wish to take an active role in this class action by petitioning to become the Lead Plaintiff.

The heart of this class action revolves around a troubling press release from Rocket, dated May 27, 2025, that disclosed a significant update regarding its gene therapy, RP-A501, designed to treat Danon disease. The release indicated that a participant in the Phase 2 pivotal trial experienced an unexpected serious adverse event, namely complications connected to capillary leak syndrome. This critical incident led Rocket to halt the study voluntarily. Adding to the severity, the FDA subsequently imposed a clinical hold on the trial for further assessment after it was revealed that the patient had tragically passed away due to an acute systemic infection.

Following this news, Rocket's shares plummeted by an astonishing 62.84%, dropping to $2.33 per share—a staggering decrease affecting many investors.

Why This Matters

The implications of this lawsuit are profound. Investors who purchased Rocket's securities during the class period could potentially recover losses if it is determined that the company acted unlawfully or engaged in deceptive practices. Pomerantz LLP, recognized as a leading firm in corporate, securities, and antitrust class litigation, aims to protect the interests of those adversely affected by the alleged malfeasance.

Founded by the influential figure Abraham L. Pomerantz, the firm has an illustrious history, having fought tirelessly for the rights of investors affected by securities fraud and corporate misconduct over the past 85 years. Pomerantz has secured numerous multimillion-dollar settlements for their clients, highlighting their commitment to justice and accountability.

Getting Involved

Investors affected by the downturn in Rocket's stock are encouraged to act swiftly. By reaching out to Pomerantz, you can learn about your rights as a shareholder and the possibility of joining the class. This presents an opportunity not only to seek potential financial recovery but also to hold Rocket accountable for its actions, fostering a culture of transparency and integrity in the biotech industry.

Conclusion

Time is of the essence for those who believed in Rocket Pharmaceuticals' potential but felt blindsided by the recent developments. The ongoing class action lawsuit may provide a platform for affected investors to seek restitution. Ensure to keep track of important deadlines and secure professional legal advice as part of your journey to reclaiming your investment. For more information or to access the complaint summary, visit Pomerantz Law.